Over PhRMA’s Objections, US FDA To Study Accelerated Approval Disclosures in DTC Ads
PhRMA argued the study is duplicative of previous project and lacks practical utility. Agency says it is replicating the prior study in a new patient population and testing additional versions of accelerated approval disclosure. Agency makes minor revisions to the study questionnaire.
You may also be interested in...
Study will assess responses of cancer survivors and caregivers to disclosures that a drug received accelerated approval. FDA analysis found that 73% of 26 accelerated approval drugs cited approval pathway on product websites.
US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.
Trade association says research projects are often unnecessary, questions studies of low-internet users and how disclosures about a product affect viewer perceptions.